Hirokazu Sugiyama

Abstract In recent years, many chemical companies have adopted the concept of sustainable development as a core business value. In this context and with focus on early phases, we present a novel design framework that comprises four stages of process modeling and multiobjective evaluation considering monetary and nonmonetary aspects. Each stage is characterized by the available information as a basis for process modeling and assessment. Appropriate modeling approaches, and evaluation indicators f

In this paper, we present activity models of chemical process design integrating environmental, health and safety (EHS) evaluation as a new element with conventional economic and technical considerations on the basis of the design framework, which defines different stages of early process design with appropriate indicators for multiobjective evaluation. The type-zero method of Integrated DEFinition language or IDEF0 is selected as an activity modeling method for the hierarchical and transparent

Nectin-like molecule 4 (Necl-4)/CADM4, a transmembrane cell-cell adhesion molecule with three Ig-like domains, was shown to serve as a tumor suppressor, but its mode of action has not been elucidated. In this study, we showed that Necl-4 interacted in cis with ErbB3 through their extracellular regions, recruited PTPN13 and inhibited the heregulin-induced activation of the ErbB2/ErbB3 signaling. In addition, we extended our previous finding that Necl-4 interacts in cis with integrin α6 β4 through

A five-step method is proposed for determining the design space of mesenchymal stem cell (MSC) cultivation processes incorporating system dynamics and variabilities. The method uses mechanistic models to capture the MSC cultivation dynamics while performing stochastic simulation to consider influences of the variabilities at raw material, cell, process specification, and operation levels. Simulated time-dependent changes in critical quality attributes (CQAs) are used to determine a dynamic and p

This work presents an uncertainty‐conscious methodology for the assessment of process performance—for example, run time—in the manufacturing of biopharmaceutical drug products. The methodology is presented as an activity model using the type 0 integrated definition (IDEF0) functional modeling method, which systematically interconnects information, tools, and activities. In executing the methodology, a hybrid stochastic–deterministic model that can reflect operational uncertainty in the assessmen